ENRICH-SARCOMA

Sarcomas are soft tissue tumors with limited treatment options, which often include radiation therapy. For some sarcomas, the benefit of radiation is limited, and enhancing its effect could improve patient outcomes. Our research has focused on radiosensitization: increasing the sensitivity of tumors to radiation. We do this via administration of drugs that enrich tumor cells […]

sideroFORCE

Each year, around 7.7 million deaths are linked to bacterial infections, with 4.95 million caused by drug-resistant pathogens. Indeed, antimicrobial resistance undermines the benefits of effective antibiotics, becoming a significant barrier towards achieving the Sustainable Development Goals related to health and poverty alleviation. Although it is of eminent importance to reduce the misuse and overuse […]

Targeting RNA Dicing

Modular Therapeutics is addressing one of the biggest challenges in medicine: many patients do not respond to existing treatments because their disease is driven by unique molecular changes that current drugs cannot target, often due to an insufficient understanding of the biological impact of these mutations. Our innovation is based on a newly discovered biological […]

EXOBOOSTER

EXIT071 is a Dutch deep-tech company, spin-off from Leiden University, based at the Leiden Bio Science Park. The company is dedicated to developing advanced exosome isolation technologies for biomarker discovery, diagnostics, and therapeutic applications. By leveraging its proprietary innovations, EXIT071 aims to accelerate the integration of exosome-based solutions into precision medicine. EXIT071 has developed a […]

NanoLoom

Molecules (proteins) that bind to DNA in our cells play a crucial role in viral and microbial infections, rare diseases, and cancer: developing drugs that interfere with the function of these proteins would allow us to tackle many medical challenges. Single-molecule approaches have greatly advanced our understanding of DNA processes in academic research, but traditional […]

Fenix Therapeutics

Fenix Therapeutics aims to reshape cancer outcomes, providing hope to patients by transforming the future of oncology through more specific and effective treatments. Our interdisciplinary team of accomplished cancer biologists, oncologists, and chemists ensures the innovative success of our approach. Together, we can transform the landscape of cancer treatment and positively impact the lives of many cancer patients and their […]

Malaria Vaccine

Every year, more than half a million people die from malaria, mainly children under five in sub-Saharan Africa. Malaria is caused by parasites that are transmitted through mosquitoes. Recently, two vaccines have become available that protect children from infection when they are bitten by infected mosquitoes. Although these vaccines will save the lives of many, […]

Constellate

CONSTELLATE helps protein-based therapeutics developers roll out life-saving drugs faster by accelerating critical analyses in drug development. To produce a protein-based therapeutic, developers employ living cells. These cells often modify the therapeutic by, for instance, attaching large sugar molecules to it. It is critical to monitor such modifications as they influence the activity and stability […]

iProtics

iProtics is developing a novel drug to treat blood cancers and autoimmune diseases more effectively and with fewer side effects than current treatments. Existing drugs inhibit both immunoproteasomes and constitutive proteasomes, causing severe side effects by damaging healthy cells. iProtics has created a first-in-class drug that selectively inhibits only immunoproteasomes, which are primarily found in […]

Hello R&D

We are HelloR&D, a liver toxicity prediction company for novel drugs, compounds and chemicals. Based on our proprietary technology, the hepatocyte-like liver organoids (HeLLOs), we are developing a comprehensive toxicity testing platform to provide mechanistic insights for drug developers. With this, we help derisking and instructing further development. We have already validated our technology to […]